Acquisition Announced

Gilead Sciences acquisition of Tubulis

US$3.1bn consideration

Announced 7 Apr 2026

Advisers

Target
Tubulis
Acquirer
Gilead Sciences
Seller
EQT Life Sciences (LSP 7 fund)
Target based in
Germany
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.